Roche and BioNTech stole the show at this year’s San Antonio Breast Cancer Symposium. The Swiss drugmaker unveiled Phase 3 data for its oral SERD
Another TIGIT program has failed in the clinic, this time in a Phase 3 study. Arcus and Gilead said on Friday that their anti-TIGIT antibody
Plus, news about BioCryst, Cycle Pharma, Applied Therapeutics, Contineum Therapeutics, Juncell Therapeutics, Cosette and Mayne Pharma: 📊 Innovent’s mazdutide shows early promise in adolescents: The
GSK has offloaded a corporate venture unit that invests in bioelectronic startups working on neuromodulation, wearables, implanted devices and other technology, Endpoints News has learned.
Tenaya Therapeutics, a company focused on developing gene therapies for heart conditions, made a series of announcements on Thursday. The biotech said the FDA has
The FDA on Thursday expanded the label for Amgen’s rare disease drug Uplizna, approving it in an autoimmune disorder that’s quickly become a hot — and crowded — area for biopharma.
Regulators gave the green light to …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844